-
Yukihiro
Haruyama,
H.
Kataoka
(2016)
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
World journal of gastroenterology, 22 1
-
S.
Viaud,
Jennifer
Ma,
Ian
Hardy,
Eric
Hampton,
B.
Benish,
Lance
Sherwood,
V.
Núñez,
Christopher
Ackerman,
Elvira
Khialeeva,
M.
Weglarz,
S.
Lee,
A.
Woods,
T.
Young
(2018)
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Proceedings of the National Academy of Sciences of the United States of America, 115
-
Wei
Zhu,
Yibing
Peng,
Lan
Wang,
Yuan
Hong,
Xiaotao
Jiang,
Qi
Li,
Heping
Liu,
Lei
Huang,
Juan
Wu,
E.
Celis,
T.
Merchen,
E.
Kruse,
Yukai
He
(2018)
Identification of α‐fetoprotein‐specific T‐cell receptors for hepatocellular carcinoma immunotherapy
Hepatology, 68
-
H.
Zeng,
R.
Zheng,
Yuming
Guo,
Siwei
Zhang,
X.
Zou,
Ning
Wang,
Limei
Zhang,
J.
Tang,
Jianguo
Chen,
K.
Wei,
Suqin
Huang,
Jian
Wang,
Liang
Yu,
De-li
Zhao,
G.
Song,
Jianshun
Chen,
Yong-zhou
Shen,
Xiaoping
Yang,
Xiao-ping
Gu,
F.
Jin,
Qi-Long
Li,
Yanhua
Li,
Hengming
Ge,
F.
Zhu,
J.
Dong,
G.
Guo,
Ming
Wu,
L.
Du,
Xibin
Sun,
Yutong
He,
M.
Coleman,
P.
Baade,
Wanqing
Chen,
X.
Yu
(2015)
Cancer survival in China, 2003–2005: A population‐based study
International Journal of Cancer, 136
-
Hong
Liu,
Yiyang
Xu,
Jingyi
Xiang,
L.
Long,
Shon
Green,
Zhiyuan
Yang,
Bryan
Zimdahl,
Jingwei
Lu,
Neal
Cheng,
Lucas
Horan,
B.
Liu,
Su
Yan,
Pei
Wang,
Juan
Diaz,
Lu
Jin,
Y.
Nakano,
Javier
Morales,
Pengbo
Zhang,
Lianxing
Liu,
B.
Staley,
S.
Priceman,
Christine
Brown,
S.
Forman,
V.
Chan,
Cheng
Liu
(2016)
Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer
Clinical Cancer Research, 23
-
A.
Posey,
R.
Schwab,
A.
Boesteanu,
Catharina
Steentoft,
U.
Mandel,
B.
Engels,
J.
Stone,
Thomas
Madsen,
K.
Schreiber,
K.
Haines,
Alexandria
Cogdill,
Taylor J.
Chen,
Decheng
Song,
J.
Scholler,
D.
Kranz,
M.
Feldman,
R.
Young,
B.
Keith,
H.
Schreiber,
H.
Clausen,
L.
Johnson,
C.
June
(2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Immunity, 44 6
-
Jennifer
Ma,
Ji
Kim,
Stephanie
Kazane,
Sei-hyun
Choi,
Hwayoung
Yun,
Min
Kim,
D.
Rodgers,
Holly
Pugh,
O.
Singer,
Sophie
Sun,
B.
Fonslow,
J.
Kochenderfer,
T.
Wright,
P.
Schultz,
T.
Young,
Chan
Kim,
Yu
Cao
(2016)
Versatile strategy for controlling the specificity and activity of engineered T cells
Proceedings of the National Academy of Sciences, 113
-
J.
Scholler,
Troy
Brady,
G.
Binder-Scholl,
W.
Hwang,
G.
Plesa,
K.
Hege,
Ashley
Vogel,
M.
Kalos,
J.
Riley,
S.
Deeks,
R.
Mitsuyasu,
W.
Bernstein,
N.
Aronson,
B.
Levine,
F.
Bushman,
C.
June
(2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Science Translational Medicine, 4
-
Qin
Fan,
Zhipeng
Chen,
Chao
Wang,
Zhuang
Liu
(2018)
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Advanced Functional Materials, 28
-
A.
Morello,
M.
Sadelain,
P.
Adusumilli
(2016)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
Cancer discovery, 6 2
-
A.
Zhu,
P.
Gold,
A.
El-Khoueiry,
T.
Abrams,
H.
Morikawa,
N.
Ohishi,
T.
Ohtomo,
P.
Philip
(2013)
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Clinical Cancer Research, 19
-
Xiaotao
Jiang,
Mingxia
Zhang,
Q.
Lai,
Xuan
Huang,
Yongyin
Li,
Jian
Sun,
W.
Abbott,
Shiwu
Ma,
J.
Hou
(2011)
Restored Circulating Invariant NKT Cells Are Associated with Viral Control in Patients with Chronic Hepatitis B
PLoS ONE, 6
-
M.
Kudo
(2016)
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
Liver Cancer, 6
-
N.
Ahmed,
V.
Salsman,
Y.
Kew,
D.
Shaffer,
S.
Powell,
Y.
Zhang,
R.
Grossman,
H.
Heslop,
S.
Gottschalk
(2010)
HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
Clinical Cancer Research, 16
-
D.
Pettitt,
Zeeshaan
Arshad,
James
Smith,
Tijana
Stanić,
G.
Holländer,
D.
Brindley
(2017)
CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.
Molecular therapy : the journal of the American Society of Gene Therapy, 26 2
-
H.
Shirakawa,
Hitomi
Suzuki,
M.
Shimomura,
M.
Kojima,
N.
Gotohda,
Shinichirou
Takahashi,
T.
Nakagohri,
M.
Konishi,
Nobuaki
Kobayashi,
T.
Kinoshitá,
T.
Nakatsura
(2009)
Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma
Cancer Science, 100
-
Keisuke
Watanabe,
S.
Terakura,
A.
Martens,
T.
Meerten,
S.
Uchiyama,
M.
Imai,
R.
Sakemura,
T.
Goto,
Ryo
Hanajiri,
N.
Imahashi,
K.
Shimada,
A.
Tomita,
H.
Kiyoi,
T.
Nishida,
T.
Naoe,
M.
Murata
(2015)
Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells
The Journal of Immunology, 194
-
C.
June,
M.
Sadelain
(2018)
Chimeric Antigen Receptor Therapy.
The New England journal of medicine, 379 1
-
Huiping
Gao,
Kesang
Li,
H.
Tu,
Xiaorong
Pan,
Hua
Jiang,
B.
Shi,
J.
Kong,
Hongyang
Wang,
Shengli
Yang,
J.
Gu,
Zonghai
Li
(2014)
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Clinical Cancer Research, 20
-
A.
Jemal,
F.
Bray,
Melissa
Center,
J.
Ferlay,
Elizabeth
Ward,
D.
Forman
(2011)
Global cancer statistics
CA: A Cancer Journal for Clinicians, 61
-
Sunitha
Kakarla,
K.
Chow,
Melinda
Mata,
D.
Shaffer,
Xiao-tong
Song,
Meng-fen
Wu,
Hao
Liu,
Lisa
Wang,
D.
Rowley,
K.
Pfizenmaier,
S.
Gottschalk
(2013)
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Molecular therapy : the journal of the American Society of Gene Therapy, 21 8
-
M.
Postow,
R.
Sidlow,
M.
Hellmann
(2018)
Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade
The New England Journal of Medicine, 378
-
Adrienne
Long,
Waleed
Haso,
J.
Shern,
Kelsey
Wanhainen,
Meera
Murgai,
M.
Ingaramo,
Jillian
Smith,
Alec
Walker,
M.
Kohler,
Vikas
Venkateshwara,
R.
Kaplan,
George
Patterson,
T.
Fry,
R.
Orentas,
C.
Mackall
(2015)
4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
Nature medicine, 21
-
Xuemei
Jiang,
Jianjun
Hu,
Diraviyam
Thirumalai,
Xiaoying
Zhang
(2016)
Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor
Frontiers in Immunology, 7
-
J.
Llovet,
S.
Ricci,
V.
Mazzaferro,
P.
Hilgard,
E.
Gane,
J.
Blanc,
A.
Oliveira,
A.
Santoro,
J.
Raoul,
A.
Forner,
M.
Schwartz,
C.
Porta,
S.
Zeuzem,
L.
Bolondi,
T.
Greten,
P.
Galle,
J.
Seitz,
I.
Borbath,
D.
Häussinger,
T.
Giannaris,
M.
Shan,
M.
Moscovici,
D.
Voliotis,
J.
Bruix
(2008)
Sorafenib in advanced hepatocellular carcinoma.
The New England journal of medicine, 359 4
-
Xiaotao
Jiang,
Jiang
Xu,
Mingfeng
Liu,
H.
Xing,
Zhiming
Wang,
Lei
Huang,
A.
Mellor,
Wei
Wang,
Sha
Wu
(2019)
Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities.
Cancer letters
-
Maria
D’Aloia,
I.
Zizzari,
B.
Sacchetti,
L.
Pierelli,
M.
Alimandi
(2018)
CAR-T cells: the long and winding road to solid tumors
Cell Death & Disease, 9
-
M.
Hudecek,
D.
Sommermeyer,
Paula
Kosasih,
Anne
Silva-Benedict,
Lingfeng
Liu,
C.
Rader,
M.
Jensen,
S.
Riddell
(2014)
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Cancer Immunology Research, 3
-
C.
Boutros,
A.
Tarhini,
É.
Routier,
O.
Lambotte,
F.
Ladurie,
F.
Carbonnel,
Hassane
Izzeddine,
A.
Marabelle,
S.
Champiat,
A.
Berdelou,
E.
Lanoy,
M.
Texier,
C.
Libenciuc,
A.
Eggermont,
J.
Soria,
C.
Mateus,
C.
Robert
(2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Nature Reviews Clinical Oncology, 13
-
Takahiro
Ishiguro,
Masamichi
Sugimoto,
Yasuko
Kinoshita,
Y.
Miyazaki,
Kiyotaka
Nakano,
H.
Tsunoda,
I.
Sugo,
I.
Ohizumi,
H.
Aburatani,
T.
Hamakubo,
T.
Kodama,
M.
Tsuchiya,
H.
Yamada‐Okabe
(2008)
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Cancer research, 68 23
-
Peter
McIntyre,
R.
Jepson,
S.
Leeder,
L.
Irwig
(1993)
A population based study
Medical Journal of Australia, 159
-
Fubo
Zhou,
W.
Shang,
Xiaoling
Yu,
Jie
Tian
(2018)
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Medicinal Research Reviews, 38
-
Renyu
Zhang,
Zhao
Zhang,
Zekun
Liu,
D.
Wei,
Xiaodong
Wu,
H.
Bian,
Zhi-Nan
Chen
(2019)
Adoptive cell transfer therapy for hepatocellular carcinoma
Frontiers of Medicine, 13
-
Long
Li,
J.
Fierer,
T.
Rapoport,
M.
Howarth
(2014)
Structural analysis and optimization of the covalent association between SpyCatcher and a peptide Tag.
Journal of molecular biology, 426 2
-
Zhiwu
Jiang,
Xiaofeng
Jiang,
Suimin
Chen,
Y.
Lai,
Xinru
Wei,
Baiheng
Li,
Simiao
Lin,
Suna
Wang,
Qiting
Wu,
Qiubin
Liang,
Qi-fa
Liu,
Muyun
Peng,
F.
Yu,
J.
Weng,
X.
Du,
D.
Pei,
Pentao
Liu,
Yao
Yao,
P.
Xue,
Peng
Li
(2017)
Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
Frontiers in Immunology, 7
-
Yiping
Yang
(2015)
Cancer immunotherapy: harnessing the immune system to battle cancer.
The Journal of clinical investigation, 125 9
-
Han
Kim,
Guoliang
Xu,
A.
Borczuk,
S.
Busch,
J.
Filmus,
M.
Capurro,
J.
Brody,
J.
Lange,
J.
D’Armiento,
P.
Rothman,
C.
Powell
(2003)
The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor.
American journal of respiratory cell and molecular biology, 29 6
-
Liora
Schultz,
C.
Mackall
(2019)
Driving CAR T cell translation forward
Science Translational Medicine, 11
-
M.
Whitlow,
D.
Filpula,
M.
Rollence,
S.
Feng,
J.
Wood
(1994)
Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv.
Protein engineering, 7 8
-
S.
Choo,
W.
Tan,
B.
Goh,
W.
Tai,
A.
Zhu
(2016)
Comparison of hepatocellular carcinoma in Eastern versus Western populations
Cancer, 122
-
Lindsey
Torre,
F.
Bray,
R.
Siegel,
J.
Ferlay,
J.
Lortet-Tieulent,
A.
Jemal
(2015)
Global cancer statistics, 2012
CA: A Cancer Journal for Clinicians, 65
-
R.
Finn,
S.
Qin,
K.
Han,
F.
Piscaglia,
A.
Baron,
Joong-Won
Park,
G.
Han,
J.
Jassem,
Jean
Blanc,
A.
Vogel,
D.
Komov,
T.
Evans,
C.
Lopez,
C.
Dutcus,
M.
Guo,
Kenichi
Saito,
S.
Kraljevic,
T.
Tamai,
M.
Ren,
A.
Cheng
(2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet, 391
-
J.
Heimbach,
L.
Kulik,
R.
Finn,
C.
Sirlin,
M.
Abecassis,
L.
Roberts,
A.
Zhu,
M.
Murad,
J.
Marrero
(2018)
AASLD guidelines for the treatment of hepatocellular carcinoma
Hepatology, 67
-
K.
Kudo,
C.
Imai,
P.
Lorenzini,
T.
Kamiya,
K.
Kono,
A.
Davidoff,
W.
Chng,
D.
Campana
(2014)
T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.
Cancer research, 74 1
-
A.
Ribas,
J.
Wolchok
(2018)
Cancer immunotherapy using checkpoint blockade
Science, 359
-
S.
Hoseini,
N.
Cheung
(2017)
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.
Cancer letters, 399
-
B.
Zakeri,
J.
Fierer,
E.
Çelik,
E.
Chittock,
U.
Schwarz-Linek,
V.
Moy,
M.
Howarth
(2012)
Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin
Proceedings of the National Academy of Sciences, 109
-
S.
Guedan,
M.
Ruella,
C.
June
(2019)
Emerging Cellular Therapies for Cancer.
Annual review of immunology, 37